[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haemorrhagic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haemorrhagic-stroke":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,60,94,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":40,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100462387","translational-immunodiagnostics-in-stroke-trims-100462387",false,"NCT05300997","Translational Immunodiagnostics in Stroke (TrImS)","Translational Immunodiagnostics in Suspected Stroke (TrImS): A Two-centre, Pragmatic, Prospective, Observational Study","TrImS","Inclusion Criteria:\n\n* Patients eligible for enrolment include:\n\n  * Adults ≥18 years of age.\n  * Suspected acute stroke. Defined as either FAST-positive, or LAPSS-positive or ROSIER\\>0\n  * Within 24 hours of symptom onset.\n  * Informed consent.\n* Control subjects will be drawn from two groups:\n\n  * Non-neurologic patients who are matched with TIA and stroke cases (AIS, HS) for age, race, gender and smoking plus one or more of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidaemia.\n  * Relatives or accompanying friends.\n* Note that we will include and collect samples from the following cases if they present as suspected stroke and are recruited \\\u003C24 hours from symptom onset.\n\n  * Any central nervous system infection, i.e. meningitis or encephalitis in the past 30 days\n  * Any form of head trauma, stroke or intracranial haemorrhage in the past 30 days\n  * Known primary or metastatic cancer involving the brain\n  * Active cancer is defined as a diagnosis of cancer, within 6 months before enrollment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer.\n  * Autoimmune diseases: such as lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis\n  * Active infectious diseases (e.g. HIV\u002FAIDS, hepatitis C)\n  * Major surgery within three months prior to the index event\n\nExclusion Criteria:\n\n* Clear onset of acute symptoms \\>24 hours.",true,"ALL","18 Years","100 Years",{"count":22,"type":23},650,"ESTIMATED","1 Year","OBSERVATIONAL","In adult patients presenting to emergency departments within 24 hours of symptom onset with suspected acute stroke, we aim:\n\n1. to identify early brain- and pathology-specific circulating, whole blood, plasma and serum panorOmic biomarkers that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis.\n2. to identify early brain- and pathology-specific, panorOmic biomarkers in saliva that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis.\n3. to derive biomarker platforms of models for early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis\n4. to validate these models in independent and external datasets",[28,29,30,31,32,33,34,35,36,37,38,39],"Acute Ischemic Stroke","Haemorrhagic Stroke","Transient Ischemic Attacks","Cardioembolic Stroke","Large-Artery Atherosclerosis (Embolus\u002FThrombosis)","Small Vessel Disease","Stroke of Other Determined Etiology","Stroke of Undetermined Etiology","Atrial Fibrillation","Stroke of Anterior Cerebral Artery","Stroke of Middle Cerebral Artery","Stroke of Basilar Artery",[41,42,43,44,45,46],"acute stroke","emergency medicine","diagnostics","molecular","genomics and transcriptomics","proteomics","RECRUITING","2026-05-07",{"date":50,"type":51},"2026-05-11","ACTUAL",{"date":53,"type":51},"2022-05-01",{"date":55,"type":23},"2027-08-31",{"name":57,"class":58},"The University of Hong Kong","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100632298","digital-application-for-stroke-health-100632298","NCT07511868","Digital Application for Stroke Health","Evaluating a Digital Health Application for Post-stroke Care and Vascular Risk Factor Management - a Multicenter Randomized Controlled Clinical Investigation","DASH","Inclusion Criteria:\n\n1. Male or female patient (biological sex) ≥18 years at the time of consent\n2. Hospitalization for acute ischemic stroke, acute haemorrhagic stroke or TIA\n3. Necessary Technical Equipment (smartphone or tablet computer) and skills\n4. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Cerebral infarction due to cerebral venous thrombosis (CVT)\n2. Severe Psychiatric Conditions\n3. Severe pre-existing cognitive impairment\n4. Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) or other patients where salt restriction is harmful.\n5. Inability to operate the device independently (assistance from a caregiver is acceptable). E.g.:\n\n   * Severe apraxia,\n   * Severe Motor Disabilities,\n   * Severe Visual Impairment\n   * Severe Communication Barriers (e.g. Severe Aphasia, Severe Dysarthria)\n6. Inability to speak and read German to a level which allows fully comprehending the meaning of everything that is said and written.\n7. Women of childbearing potential not willing to adopt effective contraceptive measures during the clinical investigation\n8. Patients who are considered to be part of the vulnerable population:\n\n   * Persons unable to give consent\n   * Minors\n   * Persons performing military service\n   * persons detained by court or official order or accommodated in accordance with the Accommodation Act, Federal Law Gazette No. 155\u002F1990\n   * Pregnant or breastfeeding women",{"count":69,"type":23},500,"INTERVENTIONAL",[72],"NA","Stroke is a leading cause of death and long-term disability worldwide. Despite substantial advances in acute stroke care, there remains a lack of evidence-based digital solutions to support patients after hospital discharge. This study evaluates the effectiveness of a digital health application (StrokeApp) designed to support patients with ischemic or hemorrhagic stroke or transient ischemic attack (TIA) in secondary prevention and recovery.\n\nIn this multicenter, randomized, controlled, open-label trial, 500 patients will be assigned in a 1:1 ratio to receive either standard care alone or standard care in combination with StrokeApp. The primary objective is to assess the impact of the application on health-related quality of life three months after discharge. Secondary and exploratory outcomes include health literacy, medication adherence, vascular risk factors, health-related behaviors, psychosocial outcomes, long-term recovery up to twelve months, as well as safety and user experience.",[29,75,76],"Ischaemic Stroke","Transient Ischemic Attack (TIA)",[78,79,80,81,82],"Digital Health Application","Post Stroke","Medical Device","App","stroke aftercare","NOT_YET_RECRUITING","2026-03-30",{"date":86,"type":51},"2026-04-06",{"date":88,"type":23},"2026-04-01",{"date":90,"type":23},"2026-12-31",{"name":92,"class":58},"VASCage GmbH",7,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":18,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":70,"phases":106,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":59},"100584525","robotic-rehabilitation-scenario-for-patients-with-neglect-100584525","NCT06890481","Robotic rEhabilitation sCenario fOr patieNts With NeglECT","Collaborative Development of a Virtual Reality Scenario, Integrated Into a Robotic Upper Limb Rehabilitation Device, for the Treatment of Unilateral Spatial Negligence (NSU) Through Mutisensory Stimulation: Feasibility and Usability Pilot Study","RECONNECT","Inclusion Criteria:\n\n* Presence of a diagnosis of right hemispheric stroke\n* Presence of a diagnosis of hemi-inattention (Apple test)\n* Presence of left hemiplegia (Fugl-Meyer Assessment Upper Limb ≤58)\n* Adjusted Montreal Cognitive Assessment \\\u003C20\n* Written informed consent\n\nExclusion Criteria:\n\n* Presence of cognitive decline prior to the event\n* Presence of previous stroke events\n* Presence of osteoarticular rigidity (e.g., ankylosis, functional limitations with traumatic or degenerative origin) or spasticity in the affected upper limb (Modified Ashworth Scale ≥3 on shoulder, elbow, or wrist)\n* Inability to maintain a sitting position\n* Presence of severe visual disabilities\n* Recent injection of botulinum toxin in the upper limb or planned injection of botulinum toxin during the study period\n* Orthopaedic, neurological, or psychiatric disorders that could interfere with the study procedures and motor or cognitive assessments\n* Unstable fractures of the upper limb\n* Severe osteoporosis\n* Skin lesions on the upper limb","20 Years","80 Years",{"count":105,"type":23},12,[72],"The goal of this pilot clinical trial is to develop an integrated motor and cognitive rehabilitation program and evaluate the usability and acceptability of a new virtual reality scenario designed for the MOTORE device. This study will focus on the rehabilitation of the upper limbs in post-stroke patients with plegia and left-sided hemi-inattention. The main questions it aims to answer are:\n\n* The evaluation of the usability and acceptability of the newly developed scenario\n* The evaluation of the effects of the new scenario on patients' hemi-inattention\n* The evaluation of changes in upper limb functional parameters\n\nParticipants will undergo a total of 13 rehabilitation sessions, each lasting 45 minutes, using the new scenario, including an initial and final assessment.",[109,110,29,111],"Stroke","Ischemic Stroke","Neglect, Hemispatial",[113,114,115,116,117,118,119],"stroke","robotics","end-effector","upper-limbs","rehabilitation","neglect","usability","2025-03-31",{"date":122,"type":51},"2025-04-03",{"date":124,"type":23},"2025-04-01",{"date":88,"type":23},{"name":127,"class":58},"Fondazione Don Carlo Gnocchi Onlus",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":59},"100514102","coagulation-disorders-in-ischaemic-and-haemorrhagic-stroke-100514102","NCT05974111","COAgulation Disorders in Ischaemic and Haemorrhagic Stroke","COADIHS","Inclusion Criteria:\n\nPresenting at the hospital with ischaemic stroke, haemorrhagic stroke, aneurysmal subarachnoid haemorrhage or any other type of non-traumatic, intracranial bleeding\n\nIn patients with minor ischemic stroke (NIHSS \\\u003C= 4) only baseline lab sampling will be performed (T0 and T0B).\n\nExclusion Criteria:\n\n* Refusal of participation by patient or legal representative\n* Traumatic intracranial (subdural, subarachnoid, epidural haematoma) bleeding\n* Patients receiving treatment with interference on coagulation (pro \u002F anti) before first sampling: in this group of patients the coagulation assessment at presentation will be excluded, further lab sampling is performed according to protocol.\n* Patients categorized as having stroke mimic will be excluded from analysis afterwards",{"count":136,"type":23},350,"In this study the investigators will assess both procoagulant and anticoagulant pathways using thrombin generation and platelet function tests; as well as neuronal ischemia using cell free DNA in all patients presenting with ischaemic and haemorrhagic stroke (including aneurysmal subarachnoid haemorraghe). Also the cross-talk between inflammation and thrombosis, so-called thrombo-inflammation is further investigated. As such the investigators aim to characterise the patient's coagulation profile before administration of any treatment. By assessing these pathways the investigators strive to detect specific markers to predict vital and functional outcome at 3 months in these patients. Finally the investigators may provide new pathophysiological insights in the course of disease following these events that can possibly improve future therapeutic strategies.",[110,29,139],"Aneurysmal Subarachnoid Hemorrhage","2024-11-12",{"date":142,"type":51},"2024-11-14",{"date":144,"type":51},"2023-05-02",{"date":146,"type":23},"2025-08-31",{"name":148,"class":58},"Ziekenhuis Oost-Limburg"]